Introduction: Dexmedetomidine hydrochloride, an imidazole compound is the pharmacologically active s-enantiomer of medetomidine. It is described chemically as (+)-4-(s)[2, 3 – (dimethylphenyl) ethyl] – 11 H-imidazole monohydrochloride. Methodology: This study was carried out on 60 patients (30 in each group) belonging to American Society of Anesthesiologists (ASA) physical status I and II and scheduled for elective general surgical, urological and gynecological surgeries. Results: In group C (Control), the basal mean SBP was 123.97±11.44. 10 min after bolus drug administration the mean SBP was 125.40±10.97 which is not statistically significant (p=0.232). In group D (Dexmedetomidine), the basal mean SBP was 126.53±9.06. 10 min after bolus drug administration and after induction the mean SBP were 108.07±10.13 and 107.03±9.95 representing a significant fall in SBP (p=0.000). Conclusion: There was marked decrease in SBP, DBP and MAP 10 min after dexmedetomidine administration.